Literature DB >> 28601508

Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations.

Ian S Cloudsdale1, John K Dickson2, Thomas E Barta2, Brian S Grella2, Emilie D Smith2, John L Kulp4, Frank Guarnieri3, John L Kulp4.   

Abstract

We have applied simulated annealing of chemical potential (SACP) to a diverse set of ∼150 very small molecules to provide insights into new interactions in the binding pocket of human renin, a historically difficult target for which to find low molecular weight (MW) inhibitors with good bioavailability. In one of its many uses in drug discovery, SACP provides an efficient, thermodynamically principled method of ranking chemotype replacements for scaffold hopping and manipulating physicochemical characteristics for drug development. We introduce the use of Constrained Fragment Analysis (CFA) to construct and analyze ligands composed of linking those fragments with predicted high affinity. This technique addresses the issue of effectively linking fragments together and provides a predictive mechanism to rank order prospective inhibitors for synthesis. The application of these techniques to the identification of novel inhibitors of human renin is described. Synthesis of a limited set of designed compounds provided potent, low MW analogs (IC50s<100nM) with good oral bioavailability (F>20-58%).
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fragment-based simulations; Hypertension; Physicochemical properties; Renin; Simulated annealing of chemical potential

Mesh:

Substances:

Year:  2017        PMID: 28601508      PMCID: PMC5553068          DOI: 10.1016/j.bmc.2017.05.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  26 in total

1.  Computational mapping identifies the binding sites of organic solvents on proteins.

Authors:  Sheldon Dennis; Tamas Kortvelyesi; Sandor Vajda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 2.  Current trends in lead discovery: are we looking for the appropriate properties?

Authors:  Tudor I Oprea
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

3.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

4.  Fast estimation of solvation free energies for diverse chemical species.

Authors:  Robert D Boyer; Richard L Bryan
Journal:  J Phys Chem B       Date:  2012-03-19       Impact factor: 2.991

5.  Ketopiperazine-based renin inhibitors: optimization of the "C" ring.

Authors:  Daniel D Holsworth; Cuiman Cai; Xue-Min Cheng; Wayne L Cody; Dennis M Downing; Noe Erasga; Chitase Lee; Noel A Powell; Jeremy J Edmunds; Michael Stier; Mehran Jalaie; Erli Zhang; Pat McConnell; Michael J Ryan; John Bryant; Tingsheng Li; Aparna Kasani; Eric Hall; Rajendra Subedi; Mohammad Rahim; Samarendra Maiti
Journal:  Bioorg Med Chem Lett       Date:  2006-02-15       Impact factor: 2.823

6.  Functionality maps of binding sites: a multiple copy simultaneous search method.

Authors:  A Miranker; M Karplus
Journal:  Proteins       Date:  1991

Review 7.  Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.

Authors:  Nicholas A Meanwell
Journal:  Chem Res Toxicol       Date:  2011-07-26       Impact factor: 3.739

Review 8.  Recent progress on the discovery of non-peptidic direct renin inhibitors for the clinical management of hypertension.

Authors:  Fumiaki Yokokawa
Journal:  Expert Opin Drug Discov       Date:  2013-04-18       Impact factor: 6.098

9.  Piperidine renin inhibitors: from leads to drug candidates.

Authors:  H P Märki; A Binggeli; B Bittner; V Bohner-Lang; V Breu; D Bur; P H Coassolo; J P Clozel; A D'Arcy; H Doebeli; W Fischli; C H Funk; J Foricher; T Giller; F Grüninger; A Guenzi; R Güller; T Hartung; G Hirth; C H Jenny; M Kansy; U Klinkhammer; T Lave; B Lohri; F C Luft; E M Mervaala; D N Müller; M Müller; F Montavon; C H Oefner; C Qiu; A Reichel; P Sanwald-Ducray; M Scalone; M Schleimer; R Schmid; H Stadler; A Treiber; O Valdenaire; E Vieira; P Waldmeier; R Wiegand-Chou; M Wilhelm; W Wostl; M Zell; R Zell
Journal:  Farmaco       Date:  2001 Jan-Feb

Review 10.  Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.

Authors:  Włodzimierz Buczko; Justyna M Hermanowicz
Journal:  Pharmacol Rep       Date:  2008 Sep-Oct       Impact factor: 3.024

View more
  1 in total

1.  Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.

Authors:  Frank Guarnieri; John L Kulp; John L Kulp; Ian S Cloudsdale
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.